5 Key Takeaways
-
1
PER-001 is a novel, long-acting endothelin antagonist administered as a bio-erodible intravitreal implant for diabetic retinopathy.
-
2
The phase 2a study showed that PER-001 improved low-luminance contrast sensitivity in patients with moderate-to-severe diabetic retinopathy.
-
3
Functional and structural improvements were observed in the PER-001 treated groups, including better visual field and reduced ischemia.
-
4
Both doses of PER-001 demonstrated benefits compared to control, with the low dose showing significant visual field improvement.
-
5
Future phase 2b/3 trials are planned for PER-001 in diabetic retinopathy and glaucoma, with potential exploration in dry AMD.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
